Breaking News Instant updates and real-time market news.

RYTM

Rhythm Pharmaceuticals

$21.48

-0.18 (-0.83%)

16:14
11/04/19
11/04
16:14
11/04/19
16:14

Rhythm Pharmaceuticals announces two Phase 3 setmelanotide trials meet endpoints

Rhythm Pharmaceuticals announced additional data from its two pivotal Phase 3 clinical trials evaluating setmelanotide for the treatment of pro-opiomelanocortin, or POMC, deficiency obesity and leptin receptor, or LEPR, deficiency obesity showing the effect of setmelanotide on body mass index, or BMI, scores and certain cardiovascular parameters. These data are being presented by study investigators in a special, late-breaking research forum during the annual meeting of The Obesity Society at ObesityWeek, Rhythm announced that both Phase 3 clinical trials of setmelanotide met their primary endpoints and all key secondary endpoints, demonstrating a statistically significant and clinically meaningful effect on weight loss and reductions in insatiable hunger, or hyperphagia, in patients with POMC deficiency obesity and LEPR deficiency obesity over the course of one year on setmelanotide treatment. Data from both trials also show that when patients withdrew from setmelanotide during a four-week placebo withdrawal period, they experienced rapid increases in weight and hunger. Setmelanotide is a melanocortin-4 receptor, or MC4R, agonist designed to target impairments in the central melanocortin pathway, which is known to regulate weight and hunger. This week's presentations include new data showing the effect of setmelanotide on BMI scores for patients older than 19 and BMI z-scores for patients younger than 19, and its effect on vital signs including diastolic blood pressure, systolic blood pressure and heart rate. Additional analyses of safety data from the Phase 3 trials in POMC deficiency obesity and and LEPR deficiency obesity continue to support that setmelanotide is generally well-tolerated.

RYTM Rhythm Pharmaceuticals
$21.48

-0.18 (-0.83%)

03/13/19
LTCO
03/13/19
INITIATION
Target $43
LTCO
Buy
Rhythm Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Michael Higgins started Rhythm Pharmaceuticals with a Buy rating and $43 price target.
03/13/19
LTCO
03/13/19
INITIATION
Target $43
LTCO
Buy
Ladenburg starts Rhythm Pharmaceuticals with Buy rating, $43 price target
Ladenburg Thalmann analyst Michael Higgins initiated coverage of Rhythm Pharmaceuticals with a Buy rating and $43 price target. Rhythm is developing setmelanotide, a novel weight-loss drug for ultra-orphan genetic obesity disorders caused by mutations in the melanocortin-4 receptor signaling pathway, Higgins tells investors in a research note. The analyst urges investors to accumulate a position ahead of upcoming 2019 milestones, particularly pro-opiomelanocortin and leptin receptor deficiency pivotal data in Q3. Target $43.
03/13/19
03/13/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CVS Health (CVS) initiated with an Outperform at Bernstein. 2. Rhythm Pharmaceuticals (RYTM) initiated with a Buy at Ladenburg. 3. Solaris Oilfield (SOI) initiated with a Buy at B. Riley FBR. 4. Americold Realty Trust (COLD) initiated with a Buy at Berenberg. 5. Cheniere Energy (LNG) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/19
STFL
07/12/19
UPGRADE
Target $34
STFL
Buy
Rhythm Pharmaceuticals upgraded to Buy from Hold at Stifel
Stifel analyst Derek Archila upgraded Rhythm Pharmaceuticals to Buy from Hold with an unchanged price target of $34. The analyst sees an attractive entry point into the shares given setmelanotide's positive Phase 2 data, which he says demonstrated a meaningful benefit on weight loss and hunger scores. Both Phase 3 studies, expected in Q3, will likely be positive and a "homerun" scenario could move the stock to the low $40 range, Archila tells investors in a research note.

TODAY'S FREE FLY STORIES

21:55
12/09/19
12/09
21:55
12/09/19
21:55
General news
Treasury Market Summary »

Treasury Market Summary:…

AUPH

Aurinia Pharmaceuticals

$15.76

0.31 (2.01%)

21:03
12/09/19
12/09
21:03
12/09/19
21:03
Syndicate
Aurinia Pharmaceuticals 11.1M share Secondary priced at $15.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GDI

Gardner Denver

$33.90

-0.19 (-0.56%)

20:08
12/09/19
12/09
20:08
12/09/19
20:08
Downgrade
Gardner Denver rating change at BTIG »

Gardner Denver downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDI

Gardner Denver

$33.90

-0.19 (-0.56%)

19:56
12/09/19
12/09
19:56
12/09/19
19:56
Downgrade
Gardner Denver rating change at BTIG »

Gardner Denver downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTCWY

Deutsche Wohnen

$0.00

(0.00%)

19:50
12/09/19
12/09
19:50
12/09/19
19:50
Downgrade
Deutsche Wohnen rating change at Goldman Sachs »

Deutsche Wohnen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEGXF

Segro

$0.00

(0.00%)

19:49
12/09/19
12/09
19:49
12/09/19
19:49
Downgrade
Segro rating change at Goldman Sachs »

Segro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BORR

Borr Drilling

$6.60

0.46 (7.49%)

19:30
12/09/19
12/09
19:30
12/09/19
19:30
Initiation
Borr Drilling initiated at Goldman Sachs »

Borr Drilling initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSG

Inseego

$6.89

-0.05 (-0.72%)

19:26
12/09/19
12/09
19:26
12/09/19
19:26
Syndicate
Breaking Syndicate news story on Inseego »

Inseego files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$30.44

16.04 (111.39%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
Forty Seven to hold an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ARQL

ArQule

$19.71

10.035 (103.77%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
ArQule »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

XNCR

Xencor

$41.41

0.39 (0.95%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
Xencor to host analyst & investor meeting »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ABR

Arbor Realty

$14.78

(0.00%)

19:20
12/09/19
12/09
19:20
12/09/19
19:20
Syndicate
Arbor Realty 6.5M share Spot Secondary priced at $14.14 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

STRM

Streamline Health

$1.25

-0.04 (-3.10%)

18:59
12/09/19
12/09
18:59
12/09/19
18:59
Hot Stocks
Streamline Health delaying Q3 results to resolve amortization charge »

Streamline Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLOK

NortonLifeLock

$25.43

-0.02 (-0.08%)

, INTC

Intel

$56.52

-0.28 (-0.49%)

18:55
12/09/19
12/09
18:55
12/09/19
18:55
Periodicals
McAfee weighs combination with NortonLifeLock, WSJ reports »

NortonLifeLock (NLOK) has…

NLOK

NortonLifeLock

$25.43

-0.02 (-0.08%)

INTC

Intel

$56.52

-0.28 (-0.49%)

AVGO

Broadcom

$314.49

-1.68 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 19

    Dec

  • 23

    Jan

TGTX

TG Therapeutics

$9.28

2.17 (30.52%)

18:55
12/09/19
12/09
18:55
12/09/19
18:55
Conference/Events
TG Therapeutics to host investor & analyst meeting »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

NTNX

Nutanix

$33.87

-0.725 (-2.10%)

18:41
12/09/19
12/09
18:41
12/09/19
18:41
Hot Stocks
Nutanix CEO: We are transitioning to a subscription-based model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

  • 16

    Dec

SFIX

Stitch Fix

$25.17

1.04 (4.31%)

, MDB

MongoDB

$131.03

-0.19 (-0.14%)

18:33
12/09/19
12/09
18:33
12/09/19
18:33
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Stitch…

SFIX

Stitch Fix

$25.17

1.04 (4.31%)

MDB

MongoDB

$131.03

-0.19 (-0.14%)

PHR

Phreesia

$29.01

-0.09 (-0.31%)

CDMO

Avid Bioservices

$5.85

0.05 (0.86%)

MTN

Vail Resorts

$231.30

-1.43 (-0.61%)

TOL

Toll Brothers

$41.40

0.515 (1.26%)

EQ

Equillium

$4.00

-0.03 (-0.74%)

SUPN

Supernus

$22.69

-0.145 (-0.63%)

A

Agilent

$81.68

-0.545 (-0.66%)

HEPA

Hepion Pharmaceuticals

$5.61

0.4 (7.68%)

ROAD

Construction Partners

$20.56

0.66 (3.32%)

CASY

Casey's General Stores

$175.33

-0.47 (-0.27%)

CHWY

Chewy

$24.17

-0.76 (-3.05%)

LVGO

Livongo Health

$27.40

-0.6 (-2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 12

    Dec

  • 18

    Dec

  • 19

    Dec

BLUE

Bluebird Bio

$76.72

-2.79 (-3.51%)

, BMY

Bristol-Myers

$61.32

1.38 (2.30%)

18:24
12/09/19
12/09
18:24
12/09/19
18:24
Hot Stocks
Bluebird Bio, Bristol-Myers present update on Phase 1 study of bb21217 »

Bluebird bio (BLUE) and…

BLUE

Bluebird Bio

$76.72

-2.79 (-3.51%)

BMY

Bristol-Myers

$61.32

1.38 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

BA

Boeing

$351.25

-2.74 (-0.77%)

18:22
12/09/19
12/09
18:22
12/09/19
18:22
Periodicals
Former Boeing employee Pierson to testify at U.S. House hearing, Reuters says »

An ex-Boeing employee who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

OXY

Occidental Petroleum

$37.34

-0.07 (-0.19%)

18:21
12/09/19
12/09
18:21
12/09/19
18:21
Hot Stocks
Occidental Petroleum director buys 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

OXY

Occidental Petroleum

$37.34

-0.07 (-0.19%)

18:14
12/09/19
12/09
18:14
12/09/19
18:14
Hot Stocks
Occidental Petroleum director buys 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

EDIT

Editas Medicine

$30.34

-0.6 (-1.94%)

18:02
12/09/19
12/09
18:02
12/09/19
18:02
Hot Stocks
Editas Medicine announces in vivo proof-of-concept data for EDIT-301 »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSB

Mesabi Trust

$23.93

0.71 (3.06%)

, CLF

Cleveland-Cliffs

$8.52

0.38 (4.67%)

17:56
12/09/19
12/09
17:56
12/09/19
17:56
Hot Stocks
Mesabi Trust initiates arbitration against Northshore Mining, Cleveland-Cliffs »

The Trustees of Mesabi…

MSB

Mesabi Trust

$23.93

0.71 (3.06%)

CLF

Cleveland-Cliffs

$8.52

0.38 (4.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFBC

First Financial Bancorp

$24.67

0.12 (0.49%)

17:51
12/09/19
12/09
17:51
12/09/19
17:51
Hot Stocks
First Financial Bancorp chairman Davis sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRE

Green Plains

$14.26

-0.49 (-3.32%)

17:47
12/09/19
12/09
17:47
12/09/19
17:47
Hot Stocks
Green Plains CEO Todd Becker sold over 607K in company shares »

Green Plains CEO Todd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.